Biology
NAD+ is a small molecule made from vitamin B3 (niacin). Cells use it in hundreds of chemical reactions, mainly to move electrons during energy production. NAD+ is also used by enzymes involved in DNA repair and cell signaling, such as sirtuins and PARPs.
Studies show that NAD+ levels fall with age and in several diseases. In animal studies, raising NAD+ improved many measures of aging and metabolism. This research led to interest in NAD+ products for people.
Precursors
The body can make NAD+ from several building blocks, called precursors. These include niacin (nicotinic acid), nicotinamide, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). NR and NMN are the most studied in recent human trials. They are sold in the US as oral dietary supplements, which are not reviewed by the FDA as drugs.
Injections and IV use
Some wellness clinics and telehealth programs offer NAD+ itself as an IV infusion or as an injection under the skin. There is no FDA-approved NAD+ drug product. NAD+ for injection is prepared by state-licensed compounding pharmacies for an individual prescription and is not an FDA-approved product.
Because NAD+ given by injection or IV is a compounded product, there is no FDA label that sets its uses, doses or side effects. A prescriber decides whether it fits each person. To compare online programs that offer NAD+ injections, see our NAD+ provider comparison.
Evidence
A 2023 review of human trials found that oral NR and NMN are safe and well tolerated in the short term and do raise NAD+ levels in the blood and other tissues. The same review found that it is still unclear whether raising NAD+ improves health outcomes in people, because most studies were small and used many different doses. A 2025 review called for larger trials to set the best dose, route and frequency, and to study long-term safety.
For other compounded treatments offered by online programs, see sermorelin.
See also
References
- Freeberg KA et al., "Dietary supplementation with NAD+-boosting compounds in humans: current knowledge and future directions", J Gerontol A Biol Sci Med Sci 2023. pubmed.ncbi.nlm.nih.gov
- Zhang J et al., "Emerging strategies, applications and challenges of targeting NAD+ in the clinic", Nat Aging 2025. pubmed.ncbi.nlm.nih.gov
- Drugs@FDA, search for approved drug products. accessdata.fda.gov
Last updated . Category: Medications. Browse all 38 WikiTelehealth entries.